
Financial Performance - The company's revenue increased by 29% from $13 million in 2021 to $16.7 million in 2022[7] - Gross profit increased by 57% from $8 million in 2021 to $12.6 million in 2022[7] - Gross margin improved by 13% from 62% in 2021 to 75% in 2022[7] - Operating loss decreased by 41% from ($14.1) million in 2021 to ($8.4) million in 2022[7] - Q4 2022 revenue increased by 29% to $5.5 million compared to $4.3 million in Q4 2021[9] - Q4 2022 gross margin increased by 35% to $4.0 million compared to $2.9 million in Q4 2021[9] - Q4 2022 gross margin percentage improved by 3% to 72%[9] Unit Growth - The company experienced strong unit growth throughout 2022, reaching 220 systems[11] - The company experienced strong unit growth throughout 2022, reaching 180,300 treatments[11] Future Outlook - The company anticipates approximately 14-20% growth in Q1 2023 compared to Q1 2022[13] - The company estimates that achieving 1% market share in the US wound market would equate to $450 million[15]